Sugi Predict

Sugi Predict / Targets / ADORA1

ADORA1

Adenosine receptor A1 · P30542 · ADORA1 on Sugi Atlas →

400,364 patent compounds predicted against ADORA1, 206,803 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL8565 SCHEMBL8565 0.58 10/20
SCHEMBL8273 SCHEMBL8273 0.59 9/20
SCHEMBL9120 SCHEMBL9120 0.59 9/20
SCHEMBL61922 SCHEMBL61922 0.53 8/20
Tinoridine Tinoridine (SCHEMBL24761) 1.00 7/20
Benzoguanamine Benzoguanamine (SCHEMBL27898) 1.00 6/20
SCHEMBL25861 SCHEMBL25861 0.75 6/20
SCHEMBL19841 SCHEMBL19841 0.69 6/20
SCHEMBL55563 SCHEMBL55563 0.58 6/20
3-Ethyladenine 3-Ethyladenine (SCHEMBL48200) 0.50 6/20
(S,R)-Mefloquine (S,R)-Mefloquine (SCHEMBL21780) 1.00 5/20
(R,R)-Mefloquine (R,R)-Mefloquine (SCHEMBL21781) 1.00 5/20
Mefloquine Mefloquine (SCHEMBL21782) 1.00 5/20
(S,R)-Mefloquine (S,R)-Mefloquine (SCHEMBL41094) 0.98 5/20
Mefloquine Mefloquine (SCHEMBL41095) 0.98 5/20
SCHEMBL41361 SCHEMBL41361 0.74 5/20
SCHEMBL67131 SCHEMBL67131 0.69 5/20
SCHEMBL38913 SCHEMBL38913 0.65 5/20
SCHEMBL62486 SCHEMBL62486 0.65 5/20
SCHEMBL67122 SCHEMBL67122 0.60 5/20

Clinical trials — most relevant to ADORA1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Stress Testing and Cardiac Magnetic Resonance PHASE4COMPLETED
Allopurinol in Schizophrenia: A Randomized Trial Administering Allopurinol vs Placebo as add-on Antipsychotics in Patients With Schizophrenia PHASE4COMPLETED
Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury? PHASE4COMPLETED
MRI and Neurodevelopment in Preterm Infants Following Administration of High-Dose Caffeine PHASE4COMPLETED
Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH) PHASE4COMPLETED
Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI PHASE4RECRUITING
PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor PHASE4UNKNOWN
Preventing Acute Kidney Injury (AKI) in Pediatric Patients PHASE3UNKNOWN
Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy PHASE3COMPLETED
Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease PHASE2/PHASE3COMPLETED
PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function PHASE3COMPLETED
PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function PHASE3COMPLETED
Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode PHASE3COMPLETED
Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention. PHASE3WITHDRAWN
Clonidine Versus Adenosine to Treat Neuropathic Pain PHASE2COMPLETED
Intermittent Hypoxia and Caffeine in Infants Born Preterm PHASE2COMPLETED
Caffeine for Motor Manifestations of Parkinson's Disease PHASE2COMPLETED
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies PHASE1COMPLETED
Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation PHASE1UNKNOWN
Effects of Aminophylline on Renal Function and Urine Volume of AKI Patient EARLY_PHASE1UNKNOWN
Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System EARLY_PHASE1COMPLETED
Double-syringe vs Single-syringe Technique of Adenosine for Termination of Regular Narrow Complex Tachycardia nanUNKNOWN
Polymorphisms, Caffeine and Sleep Disorders nanCOMPLETED
Sublingual Caffeine on Reducing Recovery Time and Postoperative Agitation in Elderly Patients Undergoing General Anesthesia nanRECRUITING
Motivational, Affective and Performance Effects of Caffeine Supplementation nanUNKNOWN
Adenosine and A2A Receptors in Human Brown Adipose Tissue nanCOMPLETED
Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia nanCOMPLETED
Poor Sleep and Inflammation in HIV-Infected Adults nanCOMPLETED
Genetic Causes of Panic Disorder nanCOMPLETED
Genetic Studies in Difficult to Treat Asthma: TENOR nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ADORA1 binder may also engage these)

ProteinNameSimilarity
P34970 — 1.000 P34970 →
P47745 — 1.000 P47745 →
Q5RF57 — 1.000 Q5RF57 →
Q60612 — 1.000 Q60612 →
P25099 — 0.999 P25099 →
P28190 — 0.996 P28190 →
P11616 — 0.995 P11616 →
P49892 — 0.983 P49892 →
Q28309 — 0.981 Q28309 →
P35342 — 0.976 P35342 →
Q0VC81 — 0.970 Q0VC81 →
Q61618 — 0.970 Q61618 →
P28647 — 0.967 P28647 →
ADORA3 Adenosine receptor A3 0.967 landscape →
P60894 — 0.961 P60894 →
P60893 — 0.960 P60893 →
Q9I919 — 0.958 Q9I919 →
P60895 — 0.957 P60895 →
O02667 — 0.957 O02667 →
Q5RBG7 — 0.956 Q5RBG7 →
GHSR Growth hormone secretagogue receptor type 1 0.953 landscape →
O08725 — 0.951 O08725 →
A5A4K9 — 0.950 A5A4K9 →
A5A4L1 — 0.949 A5A4L1 →
Q95254 — 0.948 Q95254 →
Q99P50 — 0.947 Q99P50 →
Q923Y6 — 0.946 Q923Y6 →
S1PR3 Sphingosine 1-phosphate receptor 3 0.945 landscape →
Q96RI9 — 0.944 Q96RI9 →
Q9Z0U9 — 0.944 Q9Z0U9 →